We found a match
Your institution may have rights to this item. Sign in to continue.
- Title
The effect of mesalazine therapy on quality of life in patients with mildly and moderately active ulcerative colitis.
- Authors
IRVINE, E. J.; YEH, C.‐H.; RAMSEY, D.; STIRLING, A. L.; HIGGINS, P. D. R.
- Abstract
Background Ulcerative colitis (UC) has a major impact on the quality of life (QoL) of affected patients. Patient-reported outcomes have not been thoroughly evaluated in patients with UC receiving oral mesalazine (mesalamine). Aim To examine the effect of mesalazine on QoL of patients with mildly and moderately active UC and assess the time course of change, baseline disease severity, mesalazine dose and responder status on QoL parameters. Methods Inflammatory Bowel Disease Questionnaire (IBDQ) data were combined from two double-blind, randomized, multicentre, active-controlled trials assessing 2.4 and 4.8 g/day oral delayed-release mesalazine in 687 patients. Mean score changes from baseline were compared at 3 and 6 weeks and effects of baseline severity, mesalazine dose and response to therapy were examined. Results Mesalazine significantly improved IBDQ scores at 3 and 6 weeks (mean increase, 29.6 and 39.7 points, respectively; P < 0.0001 for both). Improvement was greater for patients with moderate disease. Greater week 6 changes occurred in clinical responders than nonresponders (50.1 vs. 23.6 points, respectively; P < 0.0001). Conclusions Delayed-release oral mesalazine produces significant clinical and statistical improvements in QoL of patients with UC by 3 weeks, with further improvement at 6 weeks.
- Subjects
ULCERATIVE colitis; INFLAMMATORY bowel diseases; INTESTINAL diseases; COLON diseases; QUESTIONNAIRES; THERAPEUTICS
- Publication
Alimentary Pharmacology & Therapeutics, 2008, Vol 28, Issue 11/12, p1278
- ISSN
0269-2813
- Publication type
Article
- DOI
10.1111/j.1365-2036.2008.03854.x